Delving into the Latest Updates on hI-con1 with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

Immuno-conjugate-1, human Immuno-conjugate 1

+ [1]

Target

tissue factor

Mechanism

tissue factor inhibitors(Tissue factor inhibitors)

Therapeutic Areas

NeoplasmsCongenital DisordersEye Diseases+ [2]

Active Indication

Dystrophy, MacularUveal Melanoma

Inactive Indication

Originator Organization

Yale University

Active Organization

ICONIC AS

Yale University

Inactive Organization

Iconic Therapeutics, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 13031459

The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.

Start Date01 May 2016

Sponsor / Collaborator

Iconic Therapeutics, Inc.

NCT02358889

/ CompletedPhase 2

A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Start Date01 Feb 2015

Sponsor / Collaborator

Iconic Therapeutics, Inc.

100 Clinical Results associated with hI-con1

Login to view more data

100 Translational Medicine associated with hI-con1

Login to view more data

100 Patents (Medical) associated with hI-con1

Login to view more data

22

Literatures (Medical) associated with hI-con1

01 May 2024·Biomedicine & Pharmacotherapy

Novel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastoma

Article

Author: Korać, Aleksandra ; Stepanović, Ana ; Nikolić, Igor ; Zlatović, Mario ; Pešić, Milica ; Opsenica, Igor ; Terzić Jovanović, Nataša

Two novel hybrid compounds, CON1 and CON2, have been developed by combining sclareol (SC) and doxorubicin (DOX) into a single molecular entity. These hybrid compounds have a 1:1 molar ratio of covalently linked SC and DOX. They have demonstrated promising anticancer properties, especially in glioblastoma cells, and have also shown potential in treating multidrug-resistant (MDR) cancer cells that express the P-glycoprotein (P-gp) membrane transporter. CON1 and CON2 form nanoparticles, as confirmed by Zetasizer, transmission electron microscopy (TEM), and chemical modeling. TEM also showed that CON1 and CON2 can be found in glioblastoma cells, specifically in the cytoplasm, different organelles, nucleus, and nucleolus. To examine the anticancer properties, the U87 glioblastoma cell line, and its corresponding multidrug-resistant U87-TxR cell line, as well as patient-derived astrocytoma grade 3 cells (ASC), were used, while normal human lung fibroblasts were used to determine the selectivity. CON1 and CON2 exhibited better resistance and selectivity profiles than DOX, showing less cytotoxicity, as evidenced by real-time cell analysis, DNA damage determination, cell death induction, mitochondrial respiration, and mitochondrial membrane depolarization studies. Cell cycle analysis and the β-galactosidase activity assay suggested that glioblastoma cells die by senescence following CON1 treatment. Overall, CON1 and CON2 showed great potential as they have better anticancer features than DOX. They are promising candidates for additional preclinical and clinical studies on glioblastoma.

31 Dec 2022·Emerging Microbes & Infections

Influence of Zika virus 3′-end sequence and nonstructural protein evolution on the viral replication competence and virulence

Article

Author: Woo, Hawon ; Oh, Jong-Won ; Lee, Se-Young ; Jung, Haewon ; Kim, Seong-Jun ; Cho, Hee ; Seo, Han Young ; Kim, Minwoo ; Jung, Hae-Gwang ; Yoon, Gone ; Son, Yu-Min ; Bak, Yeonju

Zika virus (ZIKV) has been circulating in human networks over 70 years since its first appearance in Africa, yet little is known about whether the viral 3'-terminal sequence and nonstructural (NS) protein diverged genetically from ancient ZIKV have different effects on viral replication and virulence in currently prevailing Asian lineage ZIKV. Here we show, by a reverse genetics approach using an infectious cDNA clone for a consensus sequence (Con1) of ZIKV, which represents Asian ZIKV strains, and another clone derived from the MR766 strain isolated in Uganda, Africa in 1947, that the 3'-end sequence -UUUCU-3' homogeneously present in MR766 genome and the -GUCU-3' sequence strictly conserved in Asian ZIKV isolates are functionally equivalent in viral replication and gene expression. By gene swapping experiments using the two infectious cDNA clones, we show that the NS1-5 proteins of MR766 enhance replication competence of ZIKV Con1. The Con1, which was less virulent than MR766, acquired severe bilateral hindlimb paralysis when its NS1-5 genes were replaced by the counterparts of MR766 in type I interferon receptor (IFNAR1)-deficient A129 mice. Moreover, MR766 NS5 RNA-dependent RNA polymerase (RdRp) alone also rendered the Con1 virulent, despite there being no difference in RdRp activity between MR766 and Con1 NS5 proteins. By contrast, the Con1 derivatives expressing MR766 Nsps, like Con1, did not develop severe disease in wild-type mice treated with an IFNAR1 blocking antibody. Together, our findings uncover an unprecedented role for ZIKV NS proteins in determining viral pathogenicity in immunocompromised hosts.

01 May 2020·Asia-Pacific Journal of OphthalmologyQ4 · MEDICINE

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020

Q4 · MEDICINE

ReviewOA

Author: Chhablani, Jay ; Khanani, Arshad M ; Singh, Sumit Randhir ; Jhingan, Mahima ; Aziz, Aamir A ; Samanta, Anindya

AbstractAge-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily 2 types—neovascular AMD (nAMD) with the presence of choroid neovascularization and nonneovascular AMD (nnAMD) with geographic atrophy. Although there are 4 anti-vascular endothelial growth factor drugs either widely used or approved for the former, there are no current treatments for the latter. This review will highlight upcoming treatments for AMD currently in clinical trials. For nAMD: Abicipar pegol, an intravitreal anti-vascular endothelial growth factor based on designed ankyrin repeat proteins (DARPins) is currently pending approval. Conbercept and Faricimab, 2 intravitreal anti-growth factors, are currently in phase 3. Nine other upcoming agents have at least produced results in the 1B/2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.

100 Deals associated with hI-con1

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Wet Macular Degeneration	Phase 2	US	Iconic Therapeutics, Inc.	26 Mar 2018
Age Related Macular Degeneration	Phase 2	US	Iconic Therapeutics, Inc.	01 Feb 2015
Choroidal Neovascularization	Phase 2	US	Iconic Therapeutics, Inc.	01 Feb 2015
Dystrophy, Macular	Phase 2	-	Yale University	-
Dystrophy, Macular	Phase 2	-	ICONIC AS	-
Uveal Melanoma	Phase 2	-	Yale University	-
Uveal Melanoma	Phase 2	-	ICONIC AS	-
Choroid Neoplasms	Phase 1	US	Iconic Therapeutics, Inc.	01 May 2016
Wet age-related macular degeneration	Phase 1	US	Iconic Therapeutics, Inc.	01 Dec 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03452527 (DECO, CTgov)	Phase 2	Choroidal Neovascularization \| Age Related Macular Degeneration \| Wet Macular Degeneration	15	aflibercept+ICON-1 (ICON-1 Maintenance Therapy)	tmwwvufgpo(dqybkqkusa) = deoftsdqaq fxqggizgde (ounglwtcdc, ohjdiazkdl - lhfmamuzyh) View more	-	15 Mar 2021
				aflibercept+ICON-1 (ICON-1 Combination Therapy)	tmwwvufgpo(dqybkqkusa) = sibrpgeeyf fxqggizgde (ounglwtcdc, vdmjftpwns - uqaexeccfh) View more
NCT01485588 (Phase 1 Clinical Trial Targeting Tissue Factor, CTgov)	Phase 1/2	Wet age-related macular degeneration	18	hI-con1™ 300µl	dukupkrazp(oxfulynixf) = yighfecain nqdesawrck (anjcjhcczg, whhctkxghl - czsvzoexid)	-	06 Nov 2020
NCT02358889 (EMERGE, CTgov)	Phase 2	Choroidal Neovascularization \| Age Related Macular Degeneration	88	Sham injection+hI-con1 (hI-con1)	iskjxmrugk(mutnmqgsxo) = wvodarmdeu xfkdiigpyj (kjmhnlsphd, iwhysxgfbx - kabvgknizg) View more	-	24 Sep 2020
				ranibizumab+hI-con1 (hI-con1 + Ranibizumab)	iskjxmrugk(mutnmqgsxo) = qrkqkvnuyw xfkdiigpyj (kjmhnlsphd, bjmwgrpsjx - rwgurltngo) View more
NCT02771340 (CTgov)	Phase 1	Uveal Melanoma \| Choroid Neoplasms	10	ICON-1 (ICON-1 0.3 mg Singe Dose)	vimqsmvdvq(keqifeagmm) = svlwrvqjim vjzipvlntk (nmjvlwbqnh, frbhdrufok - jnrzrohdvp) View more	-	14 Sep 2020
				ICON-1 (ICON-1 0.3 mg Repeat Dosing)	vimqsmvdvq(keqifeagmm) = ctadhoclbo vjzipvlntk (nmjvlwbqnh, eyvohfzzcu - nrdiltkkmm) View more